RecruitingPhase 1Phase 2NCT07586943

SKB118 Injection in Advanced Solid Tumors

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB118 Injection in Participants With Advanced Solid Tumors

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Enrollment

530 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is a multicenter, open-label, Phase I/II clinical study. The study is divided into two parts, the SKB118 monotherapy study and the SKB118 in combination with SKB264 study.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SKB118 Injection and a drug called SKB118+SKB264 for people with advanced solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSKB118 Injection

SKB118 Injection monotherapy, iv drip, every 3 weeks (Q3W), until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

DRUGSKB118+SKB264

Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.